A61603-induced contractions of the porcine meningeal artery are mediated by α1- and α2-adrenoceptors

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 4, 2007, Pages 279-285

  Mehrotra, Suneet ^a   Gupta, Saurabh ^a   Centurión, David ^b   Villalón, Carlos M ^b   Saxena, Pramod R ^a   VandenBrink, Antoinette Maassen ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CHELERYTHRINE; CYCLIC AMP; METITEPINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; N [5 (4,5 DIHYDRO 1H IMIDAZOL 2 YL) 5,6,7,8 TETRAHYDRO 2 HYDROXY 1 NAPHTHYL]METHANESULFONAMIDE; NORADRENALIN; PHENYLEPHRINE; POTASSIUM CHLORIDE; PRAZOSIN; PROTEIN KINASE C INHIBITOR; RAUWOLSCINE; RITANSERIN; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; ISOLATION PROCEDURE; MENINGEAL ARTERY; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-ANTAGONISTS; ALKALOIDS; ANIMALS; BENZOPHENANTHRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORECASTING; FORSKOLIN; IMIDAZOLES; MENINGEAL ARTERIES; METHIOTHEPIN; NOREPINEPHRINE; OXADIAZOLES; PHENYLEPHRINE; PIPERAZINES; POTASSIUM CHLORIDE; PRAZOSIN; PROTEIN KINASE C; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RITANSERIN; SEROTONIN ANTAGONISTS; SWINE; TETRAHYDRONAPHTHALENES; VASOCONSTRICTION; YOHIMBINE;

SUIDAE; SUS;

EID: 33947275813     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00050.x     Document Type: Article

References (43)

1. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991;102:323-30.
2. 1B/1D receptor agonists in the acute treatment of migraine. In: Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA (eds). The Headaches, 3rd edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2005;469-503.
3. Arulmani U, Gupta S, MaassenVanDenBrink A, Centurión D, Villalón CM, Saxena PR. Experimental migraine models and their relevance in migraine therapy. Cephalalgia 2006;26:642-59.
4. Tfelt-Hansen P, Saxena PR, Dahlöf C et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain 2000;123 (Pt 1):9-18.
5. Mehrotra S, Gupta S, Garrelds IM et al. Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. Naunyn Schmiedeberg's Arch Pharmacol 2006;374:163-75.
6. Hoyer D, Clarke DE, Fozard JR et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
7. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 2002;45:199-210.
8. 1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomized dogs. Naunyn Schmiedeberg's Arch Pharmacol 2004;370:46-53.
9. 2-adrenoceptors. Br J Pharmacol 1999;126:585-94.
10. 2A/2C- adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol 2004;484:287-90.
11. 2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs. Br J Pharmacol 1999;127:1263-71.
12. Willems EW, Valdivia LF, Villalón CM, Saxena PR. α-Adrenoceptors and acute migraine therapy. Drug News Perspect 2002;15:140-6.
13. Willems EW, Valdivia LF, Villalón CM, Saxena PR. Possible role of α-adrenoceptor subtypes in acute migraine therapy. Cephalalgia 2003;23:245-57.
14. 1-Selective Adrenoceptor Agonists for the Treatment of Urinary Incontinence. USA patent 5610174, 1997.
15. 1-adrenergic receptor agonist, selective for the α1? receptor subtype. J Pharmacol Exp Ther 1995;274:97-103.
16. Willems EW, Heiligers JPC, De Vries P et al. A61603-induced vasoconstriction in porcine carotid vasculature: involvement of a non-adrenergic mechanism. Eur J Pharmacol 2001;417:195-201.
17. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990;172:993-9.
18. Liu Y, Cohen MV, Downey JM. Chelerythrine, a highly selective protein kinase C inhibitor, blocks the anti-infarct effect of ischemic preconditioning in rabbit hearts. Cardiovasc Drugs Ther 1994;8:881-2.
19. Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 1986;20:1-150.
20. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 1981;78:3363-7.
21. Nyborg NC, Baandrup U, Mikkelsen EO, Mulvany MJ. Active, passive and myogenic characteristics of isolated rat intramural coronary resistance arteries. Pflügers Arch 1987;410:664-70.
22. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
23. Roon KI, MaassenVanDenBrink A, Ferrari MD, Saxena PR. Bovine isolated middle cerebral artery contractions to antimigraine drugs. Naunyn Schmiedeberg's Arch Pharmacol 1999;360:591-6.
24. Abrahamsen J. Accumulation and release of adrenaline, and the modulation by adrenaline of noradrenaline release from rabbit blood vessels in vitro. Pharmacol Toxicol 1991;69 (Suppl 3):1-40.
25. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 1959;14:48-58.
26. 2-site ligand 2-BFI. Pharmacol Biochem Behav 2003;75:427-33.
27. Blaylock NA, Wilson VG. Pharmacological characterization of noradrenaline-induced contractions of the porcine isolated palmar lateral vein and palmar common digital artery. Br J Pharmacol 1995;114:694-702.
28. Wright IK, Blaylock NA, Kendall DA, Wilson VG. The relationship between density of α-adrenoceptor binding sites and contractile responses in several porcine isolated blood vessels. Br J Pharmacol 1995;114:678-88.
29. McGrath JC. Evidence for more than one type of postjunctional α-adrenoceptor. Biochem Pharmacol 1982;31:467-84.
30. McGrath JC, Brown CM, Wilson VG. Alpha-adrenoceptors: a critical review. Med Res Rev 1989;9:407-533.
31. Sjöberg T, Steen S, Skärby T, Norgren L, Andersson KE. Postjunctional α-adrenoceptors in human superficial epigastric arteries and veins. Pharmacol Toxicol 1987;60:43-50.
32. 1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR127935. Eur J Pharmacol 1996;300:141-5.
33. 1D receptors. Naunyn Schmiedeberg's Arch Pharmacol 1997;356:312-20.
34. 1- adrenoceptor subtypes. Jap J Pharmacol 2001;86:189-95.
35. 1-Adrenoceptor subtypes. Eur J Pharmacol 1999;375:261-76.
36. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-56.
37. Chai W, Garrelds IM, De Vries R, Batenburg WW, Van Kats JP, Danser AHJ. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension 2005;46:701-6.
38. IUPHAR. 3rd Major Update to IUPHAR Receptor Database. http://www.iuphar-db.org/GPCR/ReceptorFamiliesForward. December 2006.
39. Leysen J. Serotonergic binding sites. In: Vanhoutte PM (ed). Serotonin and the Cardiovascular System. New York: Raven Press; 1985;43-62.
40. 1D receptor. Br J Pharmacol 2000;131:949-57.
41. 1B receptor. Br J Pharmacol 2001;133:891-901.
42. 1B receptors. Naunyn Schmiedeberg's Arch Pharmacol 1996;353:144-56.
43. 2-receptors: comparison with ketanserin. J Pharm Pharmacol 1986;38:374-9.